InnoCare Announces Phase III Study Results of TYK2 Inhibitor Soficitinib Meet Primary Endpoint in Patients with Atomic Dermatitis
Phase 3positivesoficitinibPositive
AI Analysis
Summary
InnoCare Pharma announced positive Phase III results for soficitinib (ICP-332), a TYK2 inhibitor, which met the primary endpoint in patients with moderate-to-severe atopic dermatitis in a registrational study.
Clinical Trial Data
Phase
Phase III
Primary Endpoint
Met
Outcome Details
Primary endpoint met in registrational Phase III clinical study
Importance:8/10
Sentiment:
0.85
TYK2 inhibitoratopic dermatitisautoimmunePhase IIIprimary endpoint met
Related Companies
Read the original article
Published by GlobeNewswire Clinical Studies on July 15, 2026 11:54 AM